Form 4: Lemaitre Vascular Executive Accrues Dividend Rights

Lemaitre Vascular's Senior VP of Operations, Trent G. Kamke, reported the accrual of dividend equivalent rights tied to various restricted stock and performance share unit awards.

Summary

• Trent G. Kamke, Senior V. P., Operations at Lemaitre Vascular Inc. (LMAT), reported the acquisition of dividend equivalent rights (DERs) on September 4, 2025.
• The DERs accrued on several restricted stock unit (RSU) and Performance Share Unit (PSU) awards granted between December 2, 2020, and December 6, 2024.
• Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock and vests proportionately with its underlying award.
• Specific accruals include 0.3386 DERs (from 12/2/2020 RSU), 0.6173 DERs (from 12/11/2021 RSU), 1.2562 DERs (from 12/12/2022 RSU), 1.2562 DERs (from 12/12/2022 PSU), 1.6108 DERs (from 12/8/2023 RSU), 1.9307 DERs (from 12/8/2023 PSU), and 1.9194 DERs (from 12/6/2024 RSU).
• Following these transactions, Mr. Kamke beneficially owns a total of 87.3697 dividend equivalent rights across all reported awards.

Sentiment

Score: 6

Explanation: The filing reports routine executive compensation accruals, which are a neutral-to-slightly positive signal as they indicate continued alignment of management's interests with long-term shareholder value, without providing new operational or financial performance data.

Positives

• The accrual of dividend equivalent rights by a senior executive indicates continued alignment of management's interests with those of shareholders through long-term incentive plans.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

The accrual of dividend equivalent rights is a common component of executive compensation packages, particularly for long-term incentive plans like Restricted Stock Units (RSUs) and Performance Share Units (PSUs), prevalent across various industries, including the medical device sector where Lemaitre Vascular operates. This filing reflects standard compensation practices rather than specific industry trends.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and Performance Share Units (PSUs) with dividend equivalent rights is a standard executive compensation practice, aligning executive incentives with long-term shareholder value. Companies like Medtronic (MDT) and Boston Scientific (BSX) in the medical device industry also utilize similar equity-based incentive structures for their executives.
• The accrual of dividend equivalents ensures that executives holding unvested equity awards benefit from dividends paid to common shareholders, maintaining alignment during the vesting period.

Stakeholder Impact

• Shareholders: The accrual of DERs aligns executive incentives with shareholder returns, as the value of these rights is tied to the company's common stock and dividend payments.
• Employees (Trent G. Kamke): This represents a component of the executive's long-term compensation, reinforcing retention and performance incentives.

Next Steps

• The dividend equivalent rights will vest proportionately with their underlying restricted stock unit and performance share unit awards.

Key Dates

Recommendation

This Form 4 filing details routine accruals of dividend equivalent rights as part of an executive's long-term incentive compensation. It does not present new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment thesis. The transaction is a standard compensation event and does not provide a basis for a 'buy' or 'sell' recommendation, thus a 'hold' is appropriate.

Keywords

Lemaitre Vascular, LMAT, Form 4, Insider Transaction, Dividend Equivalent Rights, Restricted Stock Units, Performance Share Units, Executive Compensation, Trent G. Kamke